It depends on your risk tolerance: conservative investors should rotate to Merck, while high-conviction traders should wait for the full Phase 3 dataset.
Moderna’s 14% pop reflects a short-covering squeeze and repricing of pipeline optionality following Wolfe Research’s upgrade to Peer Perform. However, holding at $158+ requires high conviction: the $9.2B peak sales figure is an unadjusted wall-street model assumption across multiple indications—not active product orders—and must be split 50/50 with partner Merck. Furthermore, Moderna's trailing twelve-month revenue has declined 27.6% to $2.23B, and detailed numerical Phase 3 INTerpath-001 data (including overall survival and hazard ratios) has not yet been peer-reviewed or fully presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
